Does ceftriaxone provide coverage against Morganella morganii?

Does Ceftriaxone Cover Morganella morganii?

Yes, ceftriaxone provides reliable coverage against Morganella morganii for both skin/soft tissue infections and urinary tract infections, as explicitly stated in the FDA-approved drug label. 1

FDA-Approved Indications

The FDA drug label for ceftriaxone specifically lists Morganella morganii as a covered pathogen for:

• Skin and skin structure infections (though efficacy was studied in fewer than 10 infections for this indication) 1
• Urinary tract infections (both complicated and uncomplicated) 1

This represents the highest level of evidence—regulatory approval based on clinical efficacy data.

Clinical Evidence Supporting Coverage

Multiple research studies confirm ceftriaxone's activity against M. morganii:

• Veterinary isolates from infected leeches showed universal sensitivity to ceftriaxone 2
• Human clinical case: A patient with M. morganii liver abscess complicated by pyopericardium was successfully treated with 19 days of intravenous ceftriaxone 3
• Primate isolates demonstrated sensitivity to ceftriaxone in drug susceptibility testing 4
• Neonatal sepsis: Early-onset neonatal sepsis caused by M. morganii was successfully treated with third-generation cephalosporin (ceftriaxone or cefotaxime) plus aminoglycoside 5

Important Caveats

Resistance Concerns

Extended-spectrum beta-lactamases (ESBLs) can compromise ceftriaxone efficacy. Studies from Argentina identified CTX-M-type beta-lactamases in M. morganii isolates with unusually high resistance to ceftriaxone 6. When M. morganii produces ESBLs:

• Ceftriaxone MICs become elevated
• Clinical failures may occur despite in vitro "susceptibility"
• Carbapenems become the preferred alternative

Cross-Resistance Patterns

One study found that using ceftriaxone MIC results to predict susceptibility to other cephalosporins had higher interpretive error rates specifically for Enterobacter species and M. morganii compared to other Enterobacteriaceae 7. This suggests:

• Always obtain susceptibility testing when M. morganii is isolated
• Don't assume susceptibility based solely on class membership
• Consider local resistance patterns

Guideline Context

While M. morganii is not specifically mentioned in most treatment guidelines, ceftriaxone is recommended for empiric coverage of Gram-negative organisms in multiple clinical scenarios:

• Intra-abdominal infections: Ceftriaxone plus metronidazole is a first-line option for mild-to-moderate community-acquired infections 8, 9
• Skin/soft tissue infections: Ceftriaxone is included in regimens for necrotizing fasciitis and incisional surgical site infections 9, 10
• Peripartum infections: Ceftriaxone plus metronidazole is proposed as an alternative to traditional regimens 11

Clinical Recommendations

For confirmed M. morganii infections:

1. Verify susceptibility testing before relying on ceftriaxone—don't assume coverage
2. Standard dosing: 1-2 grams IV daily (or divided every 12 hours for severe infections)
3. Consider combination therapy with an aminoglycoside for serious infections (bacteremia, sepsis) until susceptibilities return 5
4. Switch to carbapenem (meropenem or ertapenem) if:
   • ESBL production is confirmed
   • Clinical failure occurs despite adequate ceftriaxone levels
   • MIC is elevated (≥1 mg/L)

For empiric therapy when M. morganii is a possible pathogen (urinary tract infections, intra-abdominal infections, skin/soft tissue infections), ceftriaxone is an appropriate choice pending culture results.